119 related articles for article (PubMed ID: 20871128)
1. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register.
Gäwert L; Hierse F; Zink A; Strangfeld A
Rheumatology (Oxford); 2011 Jan; 50(1):152-60. PubMed ID: 20871128
[TBL] [Abstract][Full Text] [Related]
2. [The importance of patient perspective in drug surveillance systems].
Gäwert L; Hierse F; Zink A; Strangfeld A
Z Rheumatol; 2010 Nov; 69(9):795-802. PubMed ID: 21063828
[TBL] [Abstract][Full Text] [Related]
3. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
4. [Safety of biologic therapy - results from the German biologics register RABBIT].
Strangfeld A; Zink A
Dtsch Med Wochenschr; 2014 Sep; 139(37):1817-20. PubMed ID: 25180996
[No Abstract] [Full Text] [Related]
5. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
6. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events.
Yazici Y; Erkan D; Paget SA
Arthritis Rheum; 2003 Oct; 48(10):2769-72. PubMed ID: 14558081
[TBL] [Abstract][Full Text] [Related]
7. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
8. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.
Blomqvist P; Feltelius N; Ekbom A; Klareskog L
J Rheumatol; 2000 May; 27(5):1171-7. PubMed ID: 10813283
[TBL] [Abstract][Full Text] [Related]
9. Improving the reporting of adverse drug reactions in the hospital setting.
Pushkin R; Frassetto L; Tsourounis C; Segal ES; Kim S
Postgrad Med; 2010 Nov; 122(6):154-64. PubMed ID: 21084792
[TBL] [Abstract][Full Text] [Related]
10. Reporting adverse drug reactions on a geriatric ward: a pilot project.
Somers A; Petrovic M; Robays H; Bogaert M
Eur J Clin Pharmacol; 2003 Feb; 58(10):707-14. PubMed ID: 12610749
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of cases showing adverse reactions toward many kinds of DMARDs].
Iizasa T; Matsuta K; Ito K
Ryumachi; 1995 Feb; 35(1):56-61. PubMed ID: 7732491
[TBL] [Abstract][Full Text] [Related]
12. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
Zink A; Listing J; Ziemer S; Zeidler H;
J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
[TBL] [Abstract][Full Text] [Related]
13. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
14. The British Society for Rheumatology biologics register.
Watson K; Symmons D; Griffiths I; Silman A
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv42-3. PubMed ID: 16239385
[TBL] [Abstract][Full Text] [Related]
15. Objective psychological measurement and clinical assessment of anxiety in adverse drug reactions.
Ong D; Popat A; Knowles SR; Arrowood JS; Shear NH; Binkley KE
Can J Clin Pharmacol; 2004; 11(1):e8-16. PubMed ID: 15226522
[TBL] [Abstract][Full Text] [Related]
16. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
[TBL] [Abstract][Full Text] [Related]
17. Patient reporting of adverse drug reactions: useful information for pain management?
Jarernsiripornkul N; Krska J; Richards RM; Capps PA
Eur J Pain; 2003; 7(3):219-24. PubMed ID: 12725844
[TBL] [Abstract][Full Text] [Related]
18. Ten years with biologics: to whom do data on effectiveness and safety apply?
Simard JF; Arkema EV; Sundström A; Geborek P; Saxne T; Baecklund E; Coster L; Dackhammar C; Jacobsson L; Feltelius N; Lindblad S; Rantapää-Dahlqvist S; Klareskog L; van Vollenhoven RF; Neovius M; Askling J
Rheumatology (Oxford); 2011 Jan; 50(1):204-13. PubMed ID: 21084326
[TBL] [Abstract][Full Text] [Related]
19. Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis.
Murota A; Kaneko Y; Yamaoka K; Takeuchi T
J Rheumatol; 2016 Nov; 43(11):1984-1988. PubMed ID: 27585685
[TBL] [Abstract][Full Text] [Related]
20. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.
Dixon WG; Carmona L; Finckh A; Hetland ML; Kvien TK; Landewe R; Listing J; Nicola PJ; Tarp U; Zink A; Askling J
Ann Rheum Dis; 2010 Sep; 69(9):1596-602. PubMed ID: 20525843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
